# Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease

> **NCT01085201** · PHASE1 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 39 (actual)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **DRUG:** Lexiscan

## Key facts

- **NCT ID:** NCT01085201
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04
- **Primary completion:** 2013-02
- **Final completion:** 2013-03
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2014-03-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01085201

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01085201, "Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01085201. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*